EcoDrugPlus

Porcupine O-Acyltransferase

Ensembl ID : ENSDARG00000052558
Gene Symbol: PORCN
5 Cross references
195 Possible Orthologues:

Porcupine O-Acyltransferase Like

Ensembl ID : ENSDARG00000052455
Gene Symbol: PORCNL
5 Cross references
197 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSDARG00000110727
Gene Symbol: KCNMA1
6 Cross references
244 Possible Orthologues:

Potassium Channel, Subfamily K, Member 2a

Ensembl ID : ENSDARG00000055123
Gene Symbol: KCNK2A
7 Enzyme and pathways 5 Cross references
221 Possible Orthologues:

Potassium Channel, Subfamily K, Member 2b

Ensembl ID : ENSDARG00000007151
Gene Symbol: KCNK2B
5 Cross references
214 Possible Orthologues:

Potassium Channel, Subfamily K, Member 3a

Ensembl ID : ENSDARG00000043466
Gene Symbol: KCNK3A
7 Enzyme and pathways 5 Cross references
205 Possible Orthologues:

Potassium Channel, Subfamily K, Member 9

Ensembl ID : ENSDARG00000104563
Gene Symbol: KCNK9
7 Enzyme and pathways 5 Cross references
219 Possible Orthologues:

Potassium Intermediate/small Conductance Calcium-Activated Channel, Subfamily N, Member 4

Ensembl ID : ENSDARG00000086091
Gene Symbol: KCNN4
3 Enzyme and pathways 5 Cross references
191 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSDARG00000051880
Gene Symbol: KCNJ11
12 Enzyme and pathways 5 Cross references
189 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2a

Ensembl ID : ENSDARG00000019418
Gene Symbol: KCNJ2A
15 Enzyme and pathways 5 Cross references
202 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2b

Ensembl ID : ENSDARG00000104389
Gene Symbol: KCNJ2B
5 Cross references
197 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3a

Ensembl ID : ENSDARG00000077165
Gene Symbol: KCNJ3A
5 Cross references
218 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).